[go: up one dir, main page]

SI3154594T1 - FAP-aktivirana terapevtska sredstva in z njimi povezane uporabe - Google Patents

FAP-aktivirana terapevtska sredstva in z njimi povezane uporabe

Info

Publication number
SI3154594T1
SI3154594T1 SI201531956T SI201531956T SI3154594T1 SI 3154594 T1 SI3154594 T1 SI 3154594T1 SI 201531956 T SI201531956 T SI 201531956T SI 201531956 T SI201531956 T SI 201531956T SI 3154594 T1 SI3154594 T1 SI 3154594T1
Authority
SI
Slovenia
Prior art keywords
fap
therapeutic agents
uses related
activated therapeutic
activated
Prior art date
Application number
SI201531956T
Other languages
English (en)
Inventor
William W. Bachovchin
Hung-Sen Lai
David G. Sanford
Sarah E. Poplawski
Wengen Wu
Original Assignee
Bach Biosciences, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bach Biosciences, Llc filed Critical Bach Biosciences, Llc
Publication of SI3154594T1 publication Critical patent/SI3154594T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI201531956T 2014-06-13 2015-06-15 FAP-aktivirana terapevtska sredstva in z njimi povezane uporabe SI3154594T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462011989P 2014-06-13 2014-06-13
US201462051033P 2014-09-16 2014-09-16
PCT/US2015/035798 WO2015192123A1 (en) 2014-06-13 2015-06-15 Fap-activated therapeutic agents, and uses related thereto
EP15807049.0A EP3154594B1 (en) 2014-06-13 2015-06-15 Fap-activated therapeutic agents, and uses related thereto

Publications (1)

Publication Number Publication Date
SI3154594T1 true SI3154594T1 (sl) 2023-10-30

Family

ID=54834485

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531956T SI3154594T1 (sl) 2014-06-13 2015-06-15 FAP-aktivirana terapevtska sredstva in z njimi povezane uporabe

Country Status (15)

Country Link
US (6) US10245248B2 (sl)
EP (2) EP4299134A3 (sl)
JP (4) JP6744826B2 (sl)
CN (4) CN113956325A (sl)
CA (1) CA2952051C (sl)
DK (1) DK3154594T3 (sl)
ES (1) ES2951596T3 (sl)
FI (1) FI3154594T3 (sl)
HR (1) HRP20230854T1 (sl)
HU (1) HUE063194T2 (sl)
IL (2) IL291922A (sl)
PL (1) PL3154594T3 (sl)
PT (1) PT3154594T (sl)
SI (1) SI3154594T1 (sl)
WO (1) WO2015192123A1 (sl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015192124A1 (en) 2014-06-13 2015-12-17 Trustees Of Tufts College Fap-activated therapeutic agents, and uses related thereto
HUE063194T2 (hu) 2014-06-13 2024-01-28 Bach Biosciences Llc FAP-aktivált terápiás szerek és az azokkal kapcsolatos felhasználások
WO2017189569A1 (en) * 2016-04-25 2017-11-02 Trustees Of Tufts College Multimediator dpp4 and fap inhibitors, and uses related thereto
CA3041840A1 (en) 2016-10-28 2018-05-03 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating ezh2-mediated cancer
EP3551185A4 (en) 2016-12-08 2021-07-14 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS OF TREATMENT OF CDK4 / 6 MEDIATED CANCER
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
PL3391914T3 (pl) * 2017-04-21 2021-12-20 Safe Implant Technology Aps Cząstki złota do stosowania w terapii do zapobiegania lub zmniejszania przykurczu torebki
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
WO2019154859A1 (en) * 2018-02-06 2019-08-15 Universität Heidelberg Fap inhibitor
US11472799B2 (en) * 2018-03-06 2022-10-18 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
CN108864250A (zh) * 2018-05-29 2018-11-23 北京大学 一种FAPα酶敏感的吉西他滨前体药物及其制备方法和应用
IL311536A (en) * 2018-06-04 2024-05-01 Tufts College Binder-drug conjugates activated in the microenvironment and their related uses
CA3104298A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
CA3116313A1 (en) 2018-10-17 2020-04-23 Purdue Research Foundation Fibroblast activation protein (fap) targeted imaging and therapy in fibrosis
CA3134491A1 (en) * 2019-04-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use
CN114423463B (zh) 2019-05-06 2025-09-26 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
EP4003321A4 (en) * 2019-07-22 2024-01-03 Purdue Research Foundation MULTIVALENT FIBROBLAST TARGETED AGENTS AND METHODS OF USE
JP7638664B2 (ja) 2020-01-31 2025-03-04 キヤノン株式会社 光電変換装置、光電変換システム、および移動体
CN111233955B (zh) * 2020-02-28 2022-06-10 南京缘聚医药科技有限公司 一类噻唑酮甲酰胞嘧啶衍生物及其药物用途
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
WO2022026729A1 (en) * 2020-07-31 2022-02-03 The Johns Hopkins University Fap-activated compounds for treatment of cancer
KR20230141754A (ko) * 2020-10-30 2023-10-10 아박타 라이프 사이언시스 리미티드 Fap-활성화 혈청 반감기 연장된 치료 접합체
KR20230141755A (ko) * 2020-10-30 2023-10-10 아박타 라이프 사이언시스 리미티드 효소 활성화 혈청 반감기 연장된 치료 접합체
EP4262878A1 (en) * 2020-12-17 2023-10-25 Trustees Of Tufts College Fap-activated radiotheranostics, and uses related thereto
EP4308110A4 (en) * 2021-03-16 2025-06-18 Purdue Research Foundation Compounds targeting fibroblast-activation protein and methods of use thereof
CN113018450B (zh) * 2021-05-24 2021-08-06 潍坊中医药产业技术研究院 一种具有肿瘤细胞和肿瘤相关成纤维细胞双靶向功能的药物载体、制备方法及应用
CN113845563B (zh) * 2021-09-28 2024-02-20 遵义医药高等专科学校 一种FAPα酶激活式鬼臼毒素衍生物及其制备方法与应用
WO2024008833A1 (en) 2022-07-05 2024-01-11 Alex Zounek Prodrug kit for multi-pronged chemotherapy
WO2024102956A1 (en) * 2022-11-09 2024-05-16 Purdue Research Foundation Keto-amide-based fibroblast activation protein-targeted ligand linked to an imaging or therapeutic agent, compositions and methods of use
WO2025159301A1 (ko) * 2024-01-24 2025-07-31 서울대학교산학협력단 섬유아세포 활성화 단백질에 의해 활성화되는 프로드러그 화합물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
GB9309663D0 (en) 1993-05-11 1993-06-23 Erba Carlo Spa Biologically active compounds
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5767242A (en) 1994-04-20 1998-06-16 Boehringer Ingelheim Int'l Gmbh Isolated dimeric fibroblast activation protein alpha, and uses thereof
BRPI9909660B8 (pt) 1998-03-19 2021-05-25 Vertex Pharma compostos inibidores de caspases, composição farmacêutica e uso de ditos compostos
US6613879B1 (en) 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
WO2001095943A2 (en) 2000-06-14 2001-12-20 Medarex, Inc. Prodrug compounds with an oligopeptide having an isoleucine residue
US20030232742A1 (en) * 2000-11-10 2003-12-18 Stefan Peters FAP-activated anti-tumor compounds
US20030055052A1 (en) 2000-11-10 2003-03-20 Stefan Peters FAP-activated anti-tumor compounds
GB0027552D0 (en) * 2000-11-10 2000-12-27 Boehringer Ingelheim Pharma Anti-tumor compounds
US20020155565A1 (en) 2000-11-10 2002-10-24 Pilar Garin-Chesa FAP-activated anti-tumor compounds
EP1238678A1 (en) 2001-03-08 2002-09-11 Bayer Aktiengesellschaft Enzyme-activated cytostatic conjugates with integrin ligands
DE60239679D1 (de) 2001-06-11 2011-05-19 Medarex Inc Methode für die ausarbeitung von cd10-aktivierten prodrug-verbindungen
EP1333033A1 (en) 2002-01-30 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG FAP-activated anti-tumor compounds
US20040033957A1 (en) * 2002-05-10 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg FAP-activated anti-tumor prodrugs
EP1506221A2 (en) 2002-05-10 2005-02-16 Boehringer Ingelheim Pharma GmbH & Co.KG Fap-activated anti-tumor prodrugs
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2006047214A2 (en) * 2004-10-21 2006-05-04 Igf Oncology, Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
US20100047170A1 (en) 2006-01-05 2010-02-25 Denmeade Samuel R Peptide Prodrugs
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
WO2008116053A2 (en) 2007-03-20 2008-09-25 Trustees Of Tufts College Fap-activated chemotherapeutic compounds, and methods of use thereof
CN108383893A (zh) * 2011-08-30 2018-08-10 塔夫茨大学信托人 用于治疗实体瘤的fap-活化的蛋白酶体抑制剂
AU2013234451A1 (en) 2012-03-21 2014-09-25 Bayer Intellectual Property Gmbh Use of (RS)-S-cyclopropyl-S-(4-{[4-{[1R, 2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl] amino}phenyl)sulfoximide for treating specific tumours
KR20150092109A (ko) 2012-10-16 2015-08-12 젠스페라, 아이엔씨. 주사용 암 조성물
AR093512A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados heterociclicos como moduladores de la actividad de cinasas
CA2896337C (en) * 2012-12-28 2022-08-23 Life Sciences Research Partners Vzw Minimally toxic prodrugs
HUE063194T2 (hu) 2014-06-13 2024-01-28 Bach Biosciences Llc FAP-aktivált terápiás szerek és az azokkal kapcsolatos felhasználások
WO2015192124A1 (en) 2014-06-13 2015-12-17 Trustees Of Tufts College Fap-activated therapeutic agents, and uses related thereto
JP2017529853A (ja) 2014-09-25 2017-10-12 アムジエン・インコーポレーテツド プロテアーゼにより活性化可能な二重特異性タンパク質
US11351264B2 (en) 2016-04-01 2022-06-07 Arizona Board Of Regents On Behalf Of The University Of Arizona PAR2 mimetic peptides and uses thereof
WO2017189569A1 (en) 2016-04-25 2017-11-02 Trustees Of Tufts College Multimediator dpp4 and fap inhibitors, and uses related thereto

Also Published As

Publication number Publication date
US20250108031A1 (en) 2025-04-03
JP2017519753A (ja) 2017-07-20
US20170119901A1 (en) 2017-05-04
US12121505B2 (en) 2024-10-22
IL249370B (en) 2022-06-01
JP2022116203A (ja) 2022-08-09
US20200016114A1 (en) 2020-01-16
DK3154594T3 (da) 2023-08-14
PT3154594T (pt) 2023-08-17
US20220087971A1 (en) 2022-03-24
HUE063194T2 (hu) 2024-01-28
US12053450B2 (en) 2024-08-06
US20210308090A1 (en) 2021-10-07
PL3154594T3 (pl) 2023-10-09
WO2015192123A1 (en) 2015-12-17
EP3154594B1 (en) 2023-07-19
CN113967258B (zh) 2024-07-02
CA2952051A1 (en) 2015-12-17
CN113956325A (zh) 2022-01-21
HRP20230854T1 (hr) 2023-11-10
CN113967258A (zh) 2022-01-25
EP4299134A3 (en) 2024-03-27
JP2024150608A (ja) 2024-10-23
JP7530111B2 (ja) 2024-08-07
EP3154594A4 (en) 2018-01-24
US20210275491A1 (en) 2021-09-09
CN113786495A (zh) 2021-12-14
CN106573073B (zh) 2021-09-28
IL291922A (en) 2022-06-01
US12023316B2 (en) 2024-07-02
CA2952051C (en) 2023-09-12
JP6744826B2 (ja) 2020-08-19
IL249370A0 (en) 2017-02-28
JP7093912B2 (ja) 2022-07-01
ES2951596T3 (es) 2023-10-23
CN106573073A (zh) 2017-04-19
EP3154594A1 (en) 2017-04-19
EP4299134A2 (en) 2024-01-03
FI3154594T3 (fi) 2023-08-07
US11033525B2 (en) 2021-06-15
JP2020183448A (ja) 2020-11-12
US10245248B2 (en) 2019-04-02

Similar Documents

Publication Publication Date Title
IL249370A0 (en) Fap-enabled medical substances and related uses
IL250685A0 (en) Medicinal substance induces cytotoxicity
SG10201912416QA (en) Therapeutic agents
SI3132034T1 (sl) Zdravstveni pripomočki
GB201512203D0 (en) Agents,uses and methods
GB201509893D0 (en) Therapeutic agents
SG11201608943VA (en) Substituted 4-phenylpiperidines, their preparaiton and use
GB201517263D0 (en) Therapeutic agents
GB201410816D0 (en) Therapeutic agents
GB201512215D0 (en) Agents,uses and methods
GB201408673D0 (en) Medicaments,uses and methods
GB201410216D0 (en) Therapeutic
GB201509885D0 (en) Therapeutic agents
GB201410817D0 (en) Therapeutic agents
GB201502412D0 (en) Therapeutic use
GB201608797D0 (en) Therapeutic use
GB201410815D0 (en) Therapeutic agents
GB201509888D0 (en) Therapeutic agents
PT3129398T (pt) Novos agentes médicos e usos dos mesmos
GB201513299D0 (en) Therapeutic agents
GB201418809D0 (en) Therapeutic agents and uses thereof
GB201415062D0 (en) Therapeutic
EP3197470A4 (en) Cis-gnetin h and trans-gnetin h as therapeutic agents
GB201409653D0 (en) Pyrrolobenzodiazepine therapeutic agents
GB201521767D0 (en) Therapeutic agents